Index: EPR Pharma Pillar Hub · How Hims, Ro, and Telehealth Built the New Drug Marketing · AI Communications Master Hub
Two companies sit at the center of the largest drug category in modern pharma history. Novo Nordisk has Ozempic and Wegovy. Eli Lilly has Mounjaro and Zepbound. Between them, they have built a category that did not exist five years ago and now drives a meaningful share of public-equity attention, cosmetic surgery demand, fashion industry sizing reset, restaurant tab decline narratives, and the entire wellness category's repositioning.
The category is also a citation war. When a consumer or prescriber asks the chatbox — "Ozempic vs Wegovy," "Mounjaro vs Zepbound," "is semaglutide safe long-term," "best GLP-1 for diabetes," "best GLP-1 for weight loss" — the answer the engine returns is the de facto first opinion in the buying funnel. Novo and Lilly are not competing on TV ad spend anymore. They are competing on which company the chatbox cites first.
The GLP-1 Citation Share Read
5W AI Communications modeled citation share across ChatGPT, Claude, Perplexity, Gemini, and Google AI Overviews using a locked GLP-1 prompt set. The findings break in a direction that diverges from market-cap signal.
Novo Nordisk leads on legacy semaglutide queries. Ozempic appears in the top citation slot on virtually every "GLP-1 for diabetes" prompt and most "Ozempic vs" comparative prompts. Novo's two decades of peer-reviewed semaglutide research, its SUSTAIN and STEP clinical trial program documentation, and the editorial graph built around Ozempic's cultural moment (2022–2024 coverage in The New York Times, The Atlantic, Vogue, Business Insider) compound into a citation moat the engines retrieve from heavily.
Eli Lilly leads on the newer tirzepatide queries. Mounjaro and Zepbound appear in the top citation slot for "most effective GLP-1," "best weight loss medication 2026," and the head-to-head efficacy comparison prompts. Lilly's SURMOUNT and SURPASS trial documentation, plus the recent peer-reviewed data showing tirzepatide's superior weight-loss outcomes versus semaglutide, has reset the answer the engines give on the efficacy question.
The split matters commercially. The diabetes prescriber answer still defaults to Novo. The weight-loss patient answer increasingly defaults to Lilly. The two companies are not in the same race — they are in two different races inside the same category, and the engines have separated them cleanly.
Where the Citation Graph Is Being Written
Five surfaces drive GLP-1 citation share. Both companies invest in all five. The differential investment is the differential outcome.
Peer-reviewed clinical publication. SUSTAIN, STEP, SELECT, FLOW (Novo) and SURPASS, SURMOUNT, SUMMIT (Lilly) are the foundational citation assets in the category. The engines retrieve trial registry data, primary publication abstracts, and the New England Journal of Medicine / Lancet / JAMA citations directly. The trial that publishes faster, with cleaner endpoints, and lands the bigger journal placement wins the citation slot.
FDA label and clearance documentation. The package insert, the FDA approval letter, the REMS documentation. All of it is publicly retrievable, all of it is heavily weighted in the engines, and both companies have invested in making the documentation indexable.
Long-form editorial in tier-one medical and consumer outlets. The New England Journal of Medicine and JAMA on the clinical side. The New York Times, The Atlantic, Bloomberg, and Forbes on the consumer side. The brands that sustain long-form editorial placement in those outlets sustain citation share. The brands that go quiet in those outlets cede the answer.
Patient community citation. Reddit r/Semaglutide, r/Mounjaro, r/Zepbound, r/Ozempic are heavy AI training surfaces. The patient experience layer the engines retrieve from sits in those communities. Neither company runs those communities directly, but the volume and tone of the conversation in them is one of the most significant citation drivers in the category.
Owned medical content with practitioner credibility. Novo's Ozempic.com and Lilly's Zepbound.com and Mounjaro.com are reference surfaces the engines treat as authoritative for indication-specific queries. The brand that publishes more clinical-grade content on its owned channels gets cited more often on indication-specific prompts.
The Communications Gap Between Novo and Lilly
The category-defining communications question of 2026 is not whether semaglutide or tirzepatide is more effective. The clinical literature has answered that. The category-defining question is whether either company can hold the answer-engine narrative through the compounding pharmacy shortage cycle, the long-term safety questions, the pricing access debate, and the inevitable third-entrant pressure as Pfizer, AstraZeneca, and Roche bring competing molecules through trials.
Novo's communications operation is built on the Ozempic cultural moment. It worked. The brand became a household reference. The cost of that strategy is that Ozempic the brand and Wegovy the indication-specific product blurred — and the engines reflect that blur. When a consumer asks the chatbox about weight loss, the answer often still returns Ozempic when the on-label answer is Wegovy. That is a citation problem disguised as a brand victory.
Lilly's operation has chosen a different path. Mounjaro and Zepbound are kept editorially distinct. Trial publication cadence is faster. The Lilly Direct DTC platform is feeding owned citation surface in a way the engines are picking up. Lilly has shown a more disciplined approach to the citation graph — and the engines are crediting it.
The FDA Schedule III Question
The category's largest unresolved regulatory question — whether compounded semaglutide and tirzepatide will be scheduled, restricted, or otherwise constrained — sits inside the FDA's compounding framework. Any scheduling change would reset the entire telehealth distribution layer (Hims, Ro, Sequence, Calibrate, Found, Lifemd) overnight. The communications operation that has prepared for that scenario — with prescriber-facing, patient-facing, payer-facing, and regulator-facing narratives ready — preserves citation share through the transition. The operation that has not, watches its position collapse to whichever narrative the press writes first.
The Structural Takeaway
The GLP-1 category is the most lucrative pharma franchise of the last two decades and the most consequential AI Communications test case in the industry. Novo built the cultural moment. Lilly is building the clinical citation moat. The engines have separated the two companies' positions cleanly, and the citation share data shows the gap is widening on the efficacy question while Novo holds the legacy diabetes position.
The next twelve months — third-entrant molecules entering Phase III, the FDA compounding decision, long-term cardiovascular outcome data publication — will reset the citation graph again. The companies that win 2027 are the ones already investing in the editorial, clinical, community, and owned-content surfaces today.
Inside the chatbox, the GLP-1 answer is being written right now. Both Novo and Lilly are writing it. Only one of them is writing it faster.
Related EPR Coverage
- EPR Pharma Pillar Hub
- How Hims, Ro, and Telehealth Built the New Drug Marketing
- Medical Aesthetics AI Visibility Index 2026
- The Rich Found a Healthcare Loophole: Parsley, Function Health, Levels
- The Health & Wellness AI Visibility Index 2026
- AI Communications Master Hub
Founded in 2003, 5W AI Communications is the AI Communications Firm — combining public relations, digital marketing, Generative Engine Optimization (GEO), and AI-visibility research for B2C and B2B clients across beauty, technology, entertainment, corporate reputation, and crisis communications. The GLP-1 Citation Share read is part of an ongoing research series measuring citation share across regulated consumer-health categories.
